Fasenra

This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen’s investigational asthma drug comes good in phase 3

AZ’s own interleukin-5 inhibitor (IL-5) Fasenra (benralizumab) is approved as an add-on maintenance treatment for eosinophilic asthma, while another IL-5 inhibitor from GlaxoSmithKline’s IL-5

Latest news

Novartis strengthens case for its combination asthma drug

as AstraZeneca’s asthma injection Fasenra(benralizumab).
Nucala works in rare inflammatory disease, says GSK

GSK is trying to keep the first-to-market IL-5 inhibitor ahead of other drugs in the class, particularly AstraZeneca’s Fasenra (benralizumab) which is gaining ground fast with
AZ reports growth again in Q3, driven by oncology and China sales

AZ’s respiratory franchise also grew 18% to $1.3bn – although the company saw a 4% decline in sales of Symbicort, this was offset by the growth of Pulmicort and Fasenra,
Tecentriq’s triple negative breast cancer use among key CHMP nods

The company also received a positive opinion for a new self-administration option for Fasenra (benralizumab) via a pre-filled, single-use auto-injector, rivalling similar moves from GSK and its
GSK’s Nucala gets boost with self-administration approval

it. This still leaves it at a disadvantage to Fasenra, which is administered just once every eight weeks. ... This bad news has been tempered by disappointing results for AZ's rival Fasenra in the same setting.

More from news
Approximately 7 fully matching, plus 18 partially matching documents found.

Latest Intelligence

The long and winding road to asthma breakthroughs

But GSK is not alone in the IL-5 inhibitor arena. AstraZeneca’s Fasenra is making waves with its eight-week dosing schedule and $296m in first-half sales – a 244%
AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Account Director – Creative Healthcare Communications: Competative

Healthcare Account Director: Competitive

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

PMHub

Add my company

Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...